Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer’s disease

Modulation of cellular processes by histone and non-histone protein acetylation

(2022) Maria Shvedunova et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization

(2022) Courtney A. Marshall et al.   Acta Neuropathologica Communications

SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD–mutant AML

(2021) Suruchi Pacharne et al.   Blood Advances

The interaction of SET and protein phosphatase 2A as target for cancer therapy

(2021) E.C. Dacol et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

SET‐NUP214 and MLL cooperatively regulate the promoter activity of the HoxA10 gene

(2021) Sadik Cigdem et al.   GENES TO CELLS

Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response

(2021) Yu-Ting Yen et al.   Nature Communications

Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1

(2020) Otto Kauko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models

(2020) Hui Wei et al.   Neurotherapeutics

A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

(2020) Elena Arriazu et al.   Blood Cancer Journal

SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments

(2019) Min Qin et al.   Acta Neuropathologica Communications

Loss of SET reveals both the p53-dependent and the p53-independent functions in vivo

(2019) Ning Kon et al.   Cell Death & Disease

The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction

(2019) Ryan M. De Palma et al.   FASEB JOURNAL

Post‐translational regulation could determine functional differences between SET alpha and beta isoforms in chronic lymphocytic leukaemia

(2019) Ion Cristóbal et al.   BRITISH JOURNAL OF HAEMATOLOGY

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer

(2019) Ion Cristóbal et al.   Journal of Clinical Medicine

Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”

(2019) Danilo Perrotti et al.   Science Translational Medicine

Aurora B kinase activity is regulated by SET/TAF1 on Sgo2 at the inner centromere

(2019) Yuichiro Asai et al.   JOURNAL OF CELL BIOLOGY

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer

(2018) Otto Kauko et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis

(2018) Shuhei Enjoji et al.   MOLECULAR CANCER RESEARCH

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

(2018) Rocco Piazza et al.   Nature Communications

A comprehensive and perspective view of oncoprotein SET in cancer

(2018) Buuvee Bayarkhangai et al.   Cancer Medicine

CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment

(2018) Qing Zhang et al.   Frontiers in Molecular Neuroscience

Targeting PP2A in cancer: Combination therapies

(2018) Sahar Mazhar et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back

(2018) Jukka Westermarck   FEBS Journal

How it all Started: Tau and Protein Phosphatase 2A

(2018) Chang Liu et al.   JOURNAL OF ALZHEIMERS DISEASE

p53 Function is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma

(2018) Yun Wei et al.   MOLECULAR CANCER RESEARCH

SET Oncogene is Upregulated in Pediatric Acute Lymphoblastic Leukemia

(2018) Sema Sirma Ekmekci et al.   TUMORI

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

(2018) Yu-Hsiang Huang et al.   Journal of Clinical Medicine

SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia

(2018) Danielle M. Brander et al.   BRITISH JOURNAL OF HAEMATOLOGY

SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line

(2017) Lays M. Sobral et al.   FEBS Journal

Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’

(2017) Goce Taleski et al.   FEBS LETTERS

PP32 and SET/TAF-Iβ proteins regulate the acetylation of newly synthesized histone H4

(2017) Francisco Saavedra et al.   NUCLEIC ACIDS RESEARCH

Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer

(2017) Xiaoning Yuan et al.   ONCOLOGY REPORTS

SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation

(2017) Luciana O. Almeida et al.   Oncotarget

The role of SET/I2PP2A in canine mammary tumors

(2017) Satoru Kake et al.   Scientific Reports

The zebrafish homologs of SET/I2PP2A oncoprotein: expression patterns and insights into their physiological roles during development

(2016) I. Serifi et al.   BIOCHEMICAL JOURNAL

Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode

(2016) Donglai Wang et al.   NATURE

Histone chaperone activity of Arabidopsis thaliana NRP1 is blocked by cytochrome c

(2016) Katiuska González-Arzola et al.   NUCLEIC ACIDS RESEARCH

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

(2016) Raffaella Pippa et al.   Oncotarget

Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

(2016) Nameeta P. Richard et al.   Oncotarget

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia

(2016) Elena Arriazu et al.   Frontiers in Oncology

All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase

(2015) Jaya Sangodkar et al.   FEBS Journal

Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation

(2015) Yixuan Wang et al.   NEUROBIOLOGY OF AGING

Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer

(2015) Hao Liu et al.   Oncotarget

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

(2015) Raúl Rincón et al.   Oncotarget

The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin

(2015) Alkmini Kalousi et al.   Cell Reports

Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia

(2015) Kavitha Ramaswamy et al.   Frontiers in Oncology

From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies

(2015) Maria Ciccone et al.   Frontiers in Oncology

SET-NUP214 is a recurrent    lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL

(2014) R. Ben Abdelali et al.   BLOOD

Cytoplasmic SET induces tau hyperphosphorylation through a decrease of methylated phosphatase 2A

(2014) Stéphanie Chasseigneaux et al.   BMC NEUROSCIENCE

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Inhibition of FoxO1 acetylation by INHAT subunit SET/TAF-Iβ induces p21 transcription

(2014) Yun-Cheol Chae et al.   FEBS LETTERS

Cytoplasmic Retention of Protein Phosphatase 2A Inhibitor 2 (I2PP2A) Induces Alzheimer-like Abnormal Hyperphosphorylation of Tau

(2014) Mohammad Arif et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

(2014) R Pippa et al.   LEUKEMIA

Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models

(2014) Lays M Sobral et al.   Molecular Cancer

Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

(2014) Amy S. Farrell et al.   MOLECULAR CANCER RESEARCH

PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential

(2014) I. Cristobal et al.   MOLECULAR CANCER THERAPEUTICS

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

(2014) M. Janghorban et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein phosphatase 2A dysfunction in Alzheimer’s disease

(2014) Jean-Marie Sontag et al.   Frontiers in Molecular Neuroscience

Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection

(2013) Xiaochuan Wang et al.   ACTA NEUROPATHOLOGICA

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

(2013) J. J. Oaks et al.   BLOOD

Inhibition of Ku70 acetylation by INHAT subunit SET/TAF-Iβ regulates Ku70-mediated DNA damage response

(2013) Kee-Beom Kim et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein phosphatase 2A: a target for anticancer therapy

(2013) Danilo Perrotti et al.   LANCET ONCOLOGY

Silencing PP2A Inhibitor by Lenti-shRNA Interference Ameliorates Neuropathologies and Memory Deficits in tg2576 Mice

(2013) Gong-Ping Liu et al.   MOLECULAR THERAPY

Somatic SETBP1 mutations in myeloid malignancies

(2013) Hideki Makishima et al.   NATURE GENETICS

Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease

(2013) Guang Yu et al.   NEUROBIOLOGY OF AGING

SET translocation is associated with increase in caspase cleaved amyloid precursor protein in CA1 of Alzheimer and Down syndrome patients

(2013) Patricia Facchinetti et al.   NEUROBIOLOGY OF AGING

Tau protein kinases: Involvement in Alzheimer's disease

(2012) Ludovic Martin et al.   AGEING RESEARCH REVIEWS

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

(2012) Sahar A. Saddoughi et al.   EMBO Molecular Medicine

SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates

(2012) Luciana O. Almeida et al.   FEBS Journal

H3K27 methylation and H3S28 phosphorylation-dependent transcriptional regulation by INHAT subunit SET/TAF-Iβ

(2012) Ji-Young Kim et al.   FEBS LETTERS

Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration

(2012) B. Daniel Lam et al.   FEBS LETTERS

The Apolipoprotein-E-Mimetic COG112 Protects Amyloid Precursor Protein Intracellular Domain-Overexpressing Animals from Alzheimer's Disease-Like Pathological Features

(2012) Kaushik Ghosal et al.   Neurodegenerative Diseases

Phenotypic and genetic characterization of adult T-cell acute lymphoblastic leukemia with del(9)(q34);SET-NUP214 rearrangement

(2011) Hyojin Chae et al.   ANNALS OF HEMATOLOGY

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

(2011) D. J. Christensen et al.   BLOOD

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET

(2011) Lisette Arnaud et al.   FEBS LETTERS

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

(2011) I. Cristobal et al.   HAEMATOLOGICA

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

Inhibition of Protein Phosphatase 2A Activity by PI3Kγ Regulates β-Adrenergic Receptor Function

(2011) Neelakantan T. Vasudevan et al.   MOLECULAR CELL

Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity

(2011) Ji-Young Kim et al.   NUCLEIC ACIDS RESEARCH

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

(2011) C H Switzer et al.   ONCOGENE

The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells

(2010) R. Trotta et al.   BLOOD

The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment

(2010) Xiaochuan Wang et al.   FASEB JOURNAL

Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance

(2010) Suriyan Ponnusamy et al.   Future Oncology

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

Identification of distinct SET/TAF-Iβ domains required for core histone binding and quantitative characterisation of the interaction

(2009) Zoe Karetsou et al.   BMC BIOCHEMISTRY

SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines

(2009) Hilmar Quentmeier et al.   Journal of Hematology & Oncology

The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia

(2008) P. Van Vlierberghe et al.   BLOOD

Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling

(2008) Archana Mukhopadhyay et al.   FASEB JOURNAL

Activated glucocorticoid receptor interacts with the INHAT component Set/TAF-Iβ and releases it from a glucocorticoid-responsive gene promoter, relieving repression: Implications for the pathogenesis of glucocorticoid resistance in acute undifferentiated leukemia with Set-Can translocation

(2007) Takamasa Ichijo et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms

(2007) Gong-Ping Liu et al.   NEUROBIOLOGY OF AGING